Corrigendum to “A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder”. [J Affect Disord. 15 (2020) 233-238] (Journal of Affective Disorders (2020) 15 (233-238) (S0165032719319299), (10.1016/j.jad.2020.01.050))

Ta Wei Guu, David Mischoulon, Jerome Sarris, Joseph Hibbeln, Robert K. McNamara, Kei Hamazaki, Marlene P. Freeman, Michael Maes, Yutaka J. Matsuoka, R. H. Belmaker, Wolfgang Marx, Carmine Pariante, Michael Berk, Felice Jacka, Kuan Pin Su

    Research output: Contribution to journalComment/debate


    The authors regret in the article “A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder” published in Journal of Affective Disorders on 15 March 2020, some information in the “6. Disclosure” section was omitted from the manuscript. This statement can now be found below. 6. Disclosures Dr. Guu has been a speaker and received speaker honorarium for Johnson & Johnson, Astra-Zeneca, Lundbeck and Hoan Pharmaceuticals, Standard Chem & Pharm, Pfizer, GSK Taiwan, ChenHua-Bio, Eli Lilly, Excelsior, Otsuka, EB Pharmaceutical and Servier – all unrelated to this work. Dr. Mischoulon has received research support from Nordic Naturals. He has provided unpaid consulting for Pharmavite LLC and Gnosis USA,Inc. He has received honoraria for speaking from the Massachusetts General Hospital Psychiatry Academy, Blackmores, Harvard Blog, and Peer Point Medical Education Institute, LLC. He has received royalties from Lippincott Williams & Wilkins for published book “Natural Medications for Psychiatric Disorders: Considering the Alternatives.” He also works with the MGH Clinical Trials Network and Institute (CTNI), which has received research funding from multiple pharmaceutical companies and NIMH. Dr. JR Hibbeln has received no honoraria and has no conflicts of interest. Dr. Sarris has received either presentation honoraria, travel support, clinical trial grants, book royalties, or independent consultancy payments from: Integria Healthcare & MediHerb, Pfizer, Scius Health, Key Pharmaceuticals, Australian Natural Therapies Group, Fiji Kava, Taki Mai, FIT-BioCeuticals, Blackmores, Soho-Flordis, Healthworld, HealthEd, HealthMasters, Kantar Consulting, Grunbiotics, Australian Natural Therapeutics Group, Research Reviews, Elsevier, Chaminade University, International Society for Affective Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists, ANS, Society for Medicinal Plant and Natural Product Research, SanofiAventis, Omega-3 center, the National Health and Medical Research Council, CR Roper Fellowship. Dr. Mcnamara has received investigator-initiated grant support from manufacturers of omega-3 fatty acid products including Martek Biosciences Inc (2007-2009), Royal DSM Nutritional Products, LLC (2013-2015), and the Inflammation Research Foundation (2008-2010), investigator-initiated grant support from Ortho-McNeil Janssen, NARSAD, and the national institutes of health (NIH), and previously served on the scientific advisory board of the Inflammation Research Foundation (2011-2013). Dr. Hamazaki received a research grant from the First Bank of Toyama Scholarship Foundation, speaking honoraria from the DHA&EPA Association, Niigata Medical Association, Toyama Medical Association, and Toyama Occupational Health Promotion Center, and a supervision fee from Otsuka Pharmaceutical Factory. Dr. Freeman (past 12 months): Investigator Initiated Trials /Research: JayMac, Sage; Advisory boards: Otsuka, Alkermes, Sunovion; Independent Data Safety and Monitoring Committee: Janssen (Johnson& Johnson). Dr. Freeman is an employee of Massachusetts General Hospital, and works with the MGH National Pregnancy Registry [Current Registry Sponsors: Teva (2018- present), Alkermes, Inc. (2016-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Forest/Actavis (2016-Present), Sunovion Pharmaceuticals, Inc. (2011-Present)]. As an employee of MGH, Dr. Freeman works with the MGH CTNI, which has had research funding from multiple pharmaceutical companies and NIMH. Dr. Maes has no conflict of interest. Dr. Matsuoka has received speaker's honoraria from Suntory, Pfizer, Mochida, Eli Lilly, Morinaga Milk, and NTT Data, and donation from Morinaga Milk and is conducting collaborative research with SUSMED and has conducted collaborative research with Morinaga Milk. Dr. RH Belmaker has no conflict of interest. Dr. Marx is currently funded by an Alfred Deakin Postdoctoral Research Fellowship and a Multiple Sclerosis Research Australia early-career fellowship. Wolfgang declares no conflict of interest related to this project. Wolfgang has previously received funding from the Cancer Council Queensland and university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University. Wolfgang has received industry funding and has attended events funded by Cobram Estate Pty. Ltd. Wolfgang has received travel funding from Nutrition Society of Australia. Wolfgang has received consultancy funding from Nutrition Research Australia. Wolfgang has received speakers honoraria from The Cancer Council Queensland and the Princess Alexandra Research Foundation. Dr. Pariante is funded by the UK Medical Research Council (grants MR/L014815/1, MR/J002739/1and MR/N029488/1), the European Commission Horizon 2020 (grant SC1-BHC-01-2019) and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Professor Pariante is a NIHR Senior Investigator (2017-2025). Moreover, Professor Pariante have received research funding from Johnson & Johnson for research on depression and inflammation (2012-2018) and from a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) Consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer. The work presented in this paper is unrelated to this funding. Dr. Berk has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. Dr. Jacka has received Grant/Research support from the Brain and Behavior Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical Research Foundation, theIan Potter Foundation, Eli Lilly, Meat and Livestock Australia, The A2 Milk Company, BeFit Foods, Woolworths Limited, Fernwood Foundation, Wilson Foundation, and The University of Melbourne and has received speakers honoraria from Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Health Ed, Network Nutrition, Angelini Farmaceutica, Eli Lilly and Metagenics. Felice Jacka has written two books for commercial publication and has a personal belief that good diet quality is important for mental and brain health. Dr. Su has received the following research grants related to this work: MOST 106-2314-B-039-027-MY3, 108-2320-B-039-048, 108-2813-C-039-133-B and 108-2314-B-039-016 from the Ministry of Science and Technology, Taiwan; NHRI-EX108-10528NI from the National Health Research Institutes, Taiwan; MYRG2018-00242-ICMS from University of Macau, China; CMRC-CMA-3 from Higher Education Sprout Project by the Ministry of Education (MOE), Taiwan; CMU108-SR-106 from the China Medical University, Taichung, Taiwan; and CRS-108-048, DMR-108-216 and DMR-109-102 from the China Medical University Hospital, Taichung, Taiwan. KPS has been a speaker and/or consultant for Johnson & Johnson, AstraZeneca, Lundbeck, Eli Lilly, Merck, Pfizer, Servier, Otsuka, Excelsior Biopharma, Chen Hua Biotech, Nutrarex Biotech, and Hoan Pharmaceuticals – all unrelated to this work. The authors would like to apologise for any inconvenience caused.

    Original languageEnglish
    Pages (from-to)1226-1227
    Number of pages2
    JournalJournal of Affective Disorders
    StatePublished - 1 Sep 2020

    ASJC Scopus subject areas

    • Clinical Psychology
    • Psychiatry and Mental health


    Dive into the research topics of 'Corrigendum to “A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder”. [J Affect Disord. 15 (2020) 233-238] (Journal of Affective Disorders (2020) 15 (233-238) (S0165032719319299), (10.1016/j.jad.2020.01.050))'. Together they form a unique fingerprint.

    Cite this